Therapy of Febrile Neutropenia: An Algorithm for Current Clinical Attitudes Taking into Account Cost Benefit
The treatment of febrile neutropenia has changed over the past 20 years and still is in a constant phase of reevaluation in relationship to modifications of the nature of the offending pathogens, availability of new drugs for treatment of infections and changes in the type of patients who become neutropenic as a consequence of cytostatic therapy (1).
KeywordsClin Oncol Febrile Neutropenia Empiric Therapy Neutropenic Fever Febrile Neutropenic Patient
Unable to display preview. Download preview PDF.
- 3.EORTC International Antimicrobial Therapy Cooperative Group. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever h granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995, 40:1108–1115.Google Scholar
- 6.Europen Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada — Clinical Trials Groups. Vancomycin added to empirical combination antibiotic therapy for fever h granulocytopenic cancer patients. J Infect Dis 1991, 163:951–958.CrossRefGoogle Scholar
- 9.The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993, 119:584–593.Google Scholar